Ono Pharmaceutical Co., Ltd. , Bristol Myers Squibb Co. , and Dana-Farber Cancer Institute, Inc. have entered into a global agreement to settle all disputes relating to the anti-PD-1/PD-L1 antibody. | April 10, 2023
Ono Pharmaceutical Co., Ltd. today announced that it has reviewed the targets of the medium- to long-term environment vision Environment Challenging Ono Vision for 2050 formulated in 2019 and set. | March 27, 2023
Equillium grants Ono an option to purchase rights to itolizumabEquillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone paymentsOno to fund Equillium’s continued research and development of itolizumab during the.
Published: Feb 03, 2021 By Heather McKenzie
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases with a significant medical need. Here’s a look at four of them.
Illumina and Sequoia Capital China Incubating Genomics Talent
On Monday, leading DNA sequencing and array-based technologies company,
, announceda deal with global venture capital firm, Sequoia Capital China, to incubate life sciences startups specializing in genomics.
Accepted companies will benefit from $500, 000 investment and business guidance and a minimum of $100, 000 prioritizing investments from Sequoia Capital China in the next series of financing, along with access to Illumina’s sequencing systems, reagents, and genomics knowledge.
Published: Feb 02, 2021
Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases. Here’s a look at three of them.
Illumina and Sequoia Capital China Incubating Genomics Talent
Yesterday, leading DNA sequencing and array-based technologies company, Illumina, announced a deal with global venture capital firm, Sequoia Capital China, to incubate life sciences startups specializing in genomics.
Accepted companies will benefit from $500, 000 investment and business guidance and a minimum of $100, 000 prioritizing investments from Sequoia Capital China in the next series of financing, along with access to Illumina’s sequencing systems, reagents, and genomics knowledge.